When Antibodies Persist: A Case of Graft-vs.-Host Disease-Associated NELL-1 Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0715; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Despite 2 doses of IV rituximab over 4 weeks in addition to chronic axatilimab, nephrotic-range proteinuria persisted...He was initiated on hemodialysis, cyclophosphamide, and plasma exchange (PLEX)...However, given ongoing circulating anti-NELL1 antibody, he completed an additional 2 sessions of PLEX and a total of 8 weeks of cyclosporine...Serial monitoring of circulating NELL1 antibodies may help guide disease activity assessment. Further development of an ELISA test could provide quantitative information on antibody titers to direct tailored immunosuppressive management."
Clinical • Acute Myelogenous Leukemia • Glomerulonephritis • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Nephrology • NELL1
|
|
Nupur Mistry; Wooin Ahn; Nathaniel J. Hocker; Madison Stanaway; Rupali S. Avasare
|